The cytologic findings of dysfunctional uterine bleeding due to anovulatory cycle

Comparison on serum biomarkers for anovulatory and ovulatory dysfunctional uterine bleeding in Lizu females.

OBJECTIVE To screen, identify, and compare the serum biomarkers between anovulatory dysfunctional uterine bleeding (ADUB) and ovulatory dysfunctional uterine bleeding (ODUB) in Lizu females. METHODS The subjects included 128 ADUB patients, 63 ODUB patients, and 93 controls. The serum and supernate of the subjects' mense were collected and stored at -80 °C until use. Differential proteins in t...

The management of dysfunctional uterine bleeding.

The Management of Dysfunctional Uterine Bleeding

Abnormal uterine bleeding is one of the most common reasons for women to seek for care. Dysfunctional uterine bleeding describes the spectrum of abnormal bleeding patterns in the abscence of a medical illness or pelvic pathology. It is responsible for about half of the women with abnormal uterine bleeding in reproductive age (Ewenstein, 1996). It mainly presents as menorrhagia, hence, the term ...

Clinco-Pathological Patterns in Women with Dysfunctional Uterine Bleeding

Background: The term dysfunctional uterine bleeding(DUB) refers to any abnormal bleeding from the uterus, unassociated with tumour, inflammation and pregnancy. The histological diagnosis of DUB is very essential for adequate management especially in perimenopausal and postmenopausal females. The present study was undertaken with the aim of evaluating DUB in various age groups, carry out histopa...

Management of hematometrocolpos due to dysfunctional uterine bleeding following progestin use: a case report

Hematometrocolpos is accumulation of blood in the vagina and uterine cavity due to intra-uterine hemorrhage. A 20-year-old female presented to our clinic with massive menorrhagia at menarche after progestin usage. Hematometrocolpos was detected by transabdominal ultrasonography. She was pale because of heavy bleeding for 5 days and hemoglobin level was measured as 5.1 g/dl. Initial treatment wa...